Cancer of the back of the mouth and throat is on the rise, primarily because of more cases stemming from a viral infection called human papillomavirus (HPV), according to an Ohio State University study.
The study said that the number of people who were diagnosed with HPV-related oral cancer in 2004 was triple the number diagnosed in 1988, due largely to changes in sexual behavior that have helped spread the virus.
HPV is a common sexually transmitted infection that can cause genital warts and certain cancers, including of the cervix, anus and penis.
“The whole relationship between HPV-related head and neck cancer completely changes our ideas of who is at risk, how to treat the cancer, the prognostics of the cancer, and prevention,” said Maura Gillison, who led the study, published in the Journal of Clinical Oncology.
Gillison and her colleagues examined oral cancer tissue collected from 271 patients over a 20-year period.
The type of cancer they examined, oropharyngeal, originates in the back of the tongue, the soft part of the roof of the mouth, the tonsils, or the side of the throat.
They checked the samples for evidence of HPV infection and found that the HPV-related cases became more and more common each decade, while those samples that didn’t test positive for the virus became less common.
From these results, they estimate that HPV-related oral cancers afflict 26 out of every million people in the United States, compared to eight out of every million people in 1988.
Previously, tobacco had been the primary cause of oral cancer, and most oral cancer cases were HPV-negative.
Gillison’s group found that HPV-negative cancers have been cut in half since the 1980s. HPV-positive cases, which had made up just 16 percent of oral cancer cases in the 1980s, comprised more than 70 percent in the 2000s.
The good news is that people diagnosed with the HPV-positive form of the cancer have a better prognosis, and the cancer is more responsive to treatment, Gillison said.
There is also a potential opportunity for prevention using an HPV vaccine that is approved to prevent cervical and anal cancer, she said. If the vaccine can prevent these HPV-caused cancers, perhaps it can work for oropharyngeal cancers too.
Gillison and her colleagues have received research funds or consulting jobs through the companies that sell HPV vaccines, and one of the companies is a financial contributor to an organization that helped fund the study.
For more news and information about cancer, visit www.cancertreatment.net